These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 7988041)

  • 1. Estradiol receptors in combination with neu or myc oncogene amplifications might define new subtypes of breast cancer.
    Bolufer P; Molina R; Ruiz A; Hernandez M; Vazquez C; Lluch A
    Clin Chim Acta; 1994 Sep; 229(1-2):107-22. PubMed ID: 7988041
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic significance of c-erbB-2/neu amplification and epidermal growth factor receptor (EGFR) in primary breast cancer and their relation to estradiol receptor (ER) status.
    Torregrosa D; Bolufer P; Lluch A; López JA; Barragán E; Ruiz A; Guillem V; Munárriz B; García Conde J
    Clin Chim Acta; 1997 Jun; 262(1-2):99-119. PubMed ID: 9204213
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Specific oncological contribution of cathepsin D and pS2 in human breast cancer: their relationship with TNM status, estradiol receptors, epidermal growth factor receptor and neu amplification.
    Bolufer P; Torregrosa MD; Gomez L; Munarriz B; López JA; Asins E; Espinoza S; Vera F; Vazquez C; Guillem V
    Clin Chim Acta; 1996 Mar; 247(1-2):89-103. PubMed ID: 8920230
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Int-2/FGF3 amplification is a better independent predictor of relapse than c-myc and c-erbB-2/neu amplifications in primary human breast cancer.
    Champème MH; Bièche I; Hacène K; Lidereau R
    Mod Pathol; 1994 Dec; 7(9):900-5. PubMed ID: 7892157
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nonrandom distribution of oncogene amplifications in bilateral breast carcinomas: Possible role of host factors and survival bias.
    Suspitsin EN; Sokolenko AP; Togo AV; Lazareva YR; Turkevich EA; Matsko DE; Henrich KO; Borresen-Dale AL; Schwab M; Cornelisse CJ; Imyanitov EN
    Int J Cancer; 2007 Jan; 120(2):297-302. PubMed ID: 17066426
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic relevance of gene amplifications and coamplifications in breast cancer.
    Al-Kuraya K; Schraml P; Torhorst J; Tapia C; Zaharieva B; Novotny H; Spichtin H; Maurer R; Mirlacher M; Köchli O; Zuber M; Dieterich H; Mross F; Wilber K; Simon R; Sauter G
    Cancer Res; 2004 Dec; 64(23):8534-40. PubMed ID: 15574759
    [TBL] [Abstract][Full Text] [Related]  

  • 7. c-erbB-2 (HER-2/neu) gene amplification is a better indicator of poor prognosis than protein over-expression in operable breast-cancer patients.
    Riou G; Mathieu MC; Barrois M; Le Bihan ML; Ahomadegbe JC; Bénard J; Lê MG
    Int J Cancer; 2001 Jul; 95(4):266-70. PubMed ID: 11400121
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantitation of HER-2/neu and c-myc gene amplification in breast carcinoma using fluorescence in situ hybridization.
    Persons DL; Borelli KA; Hsu PH
    Mod Pathol; 1997 Jul; 10(7):720-7. PubMed ID: 9237184
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oncogene amplifications in early-stage human prostate carcinomas.
    Latil A; Baron JC; Cussenot O; Fournier G; Boccon-Gibod L; Le Duc A; Lidereau R
    Int J Cancer; 1994 Dec; 59(5):637-8. PubMed ID: 7960236
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mapping of DNA amplifications at 15 chromosomal localizations in 1875 breast tumors: definition of phenotypic groups.
    Courjal F; Cuny M; Simony-Lafontaine J; Louason G; Speiser P; Zeillinger R; Rodriguez C; Theillet C
    Cancer Res; 1997 Oct; 57(19):4360-7. PubMed ID: 9331099
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlation of C-myc and HER-2/neu amplification and expression with histopathologic variables in uterine corpus cancer.
    Monk BJ; Chapman JA; Johnson GA; Brightman BK; Wilczynski SP; Schell MJ; Fan H
    Am J Obstet Gynecol; 1994 Nov; 171(5):1193-8. PubMed ID: 7977518
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic factors in human primary breast cancer: comparison of c-myc and HER2/neu amplification.
    Berns EM; Foekens JA; van Putten WL; van Staveren IL; Portengen H; de Koning WC; Klijn JG
    J Steroid Biochem Mol Biol; 1992 Sep; 43(1-3):13-9. PubMed ID: 1356012
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DNA amplifications at 20q13 and MDM2 define distinct subsets of evolved breast and ovarian tumours.
    Courjal F; Cuny M; Rodriguez C; Louason G; Speiser P; Katsaros D; Tanner MM; Zeillinger R; Theillet C
    Br J Cancer; 1996 Dec; 74(12):1984-9. PubMed ID: 8980401
    [TBL] [Abstract][Full Text] [Related]  

  • 14. c-myc amplification is a better prognostic factor than HER2/neu amplification in primary breast cancer.
    Berns EM; Klijn JG; van Putten WL; van Staveren IL; Portengen H; Foekens JA
    Cancer Res; 1992 Mar; 52(5):1107-13. PubMed ID: 1737370
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chromosome 11q13, c-erbB-2, and c-myc amplification in invasive breast carcinoma: clinicopathologic correlations.
    Gaffey MJ; Frierson HF; Williams ME
    Mod Pathol; 1993 Nov; 6(6):654-9. PubMed ID: 7905628
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oncogene amplification correlates with dense lymphocyte infiltration in human breast cancers: a role for hematopoietic growth factor release by tumor cells?
    Tang RP; Kacinski B; Validire P; Beuvon F; Sastre X; Benoit P; dela Rochefordière A; Mosseri V; Pouillart P; Scholl S
    J Cell Biochem; 1990 Nov; 44(3):189-98. PubMed ID: 1980125
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Amplification of HER-2(erbB-2/neu) oncogene as the most significant prognostic factor in a group of Russian breast cancer patients.
    Imyanitov EN; Chernitsa OI; Serova OM; Nikoforova IF; Pluzhnikova GF; Knyazev PG
    Neoplasma; 1993; 40(1):35-9. PubMed ID: 7688867
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Classical gene amplifications in human breast cancer are not associated with distant solid metastases.
    Driouch K; Champème MH; Beuzelin M; Bièche I; Lidereau R
    Br J Cancer; 1997; 76(6):784-7. PubMed ID: 9310246
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Significance of HER2 and C-MYC oncogene amplifications in breast cancer in atomic bomb survivors: associations with radiation exposure and histologic grade.
    Miura S; Nakashima M; Ito M; Kondo H; Meirmanov S; Hayashi T; Soda M; Matsuo T; Sekine I
    Cancer; 2008 May; 112(10):2143-51. PubMed ID: 18348306
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic alterations of c-myc, c-erbB-2, and c-Ha-ras protooncogenes and clinical associations in human breast carcinomas.
    Garcia I; Dietrich PY; Aapro M; Vauthier G; Vadas L; Engel E
    Cancer Res; 1989 Dec; 49(23):6675-9. PubMed ID: 2573420
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.